REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012

Feb 8, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-02-06

Reporting Person: GOLDBERG MURRAY A (SVP Finance and Admin CFO Trea)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-02-06	Common Stock	M	18750	$16.8	Acquired	105861	Direct
2012-02-06	Common Stock	F	3206	$98.23	Disposed	102655	Direct
2012-02-06	Common Stock	F	7160	$98.23	Disposed	95495	Direct
2012-02-06	Common Stock	M	9375	$21.25	Acquired	104870	Direct
2012-02-06	Common Stock	F	2027	$98.23	Disposed	102843	Direct
2012-02-06	Common Stock	F	3384	$98.23	Disposed	99459	Direct
2012-02-06	Common Stock	M	12788	$24.86	Acquired	112247	Direct
2012-02-06	Common Stock	F	3236	$98.23	Disposed	109011	Direct
2012-02-06	Common Stock	F	4400	$98.23	Disposed	104611	Direct
2012-02-07	Common Stock	S	13265	$99.67	Disposed	91346	Direct
2012-02-07	Common Stock	S	3735	$100.42	Disposed	87611	Direct
2012-02-07	Common Stock	S	500	$101.35	Disposed	87111	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-02-06	Non-Qualified Stock Option (right to buy)	$16.8	M	18750	Disposed	2018-12-17	Common Stock (18750)	Direct
2012-02-06	Non-Qualified Stock Option (right to buy)	$21.25	M	9375	Disposed	2019-12-18	Common Stock (9375)	Direct
2012-02-06	Non-Qualified Stock Option (right to buy)	$24.86	M	12788	Disposed	2014-12-15	Common Stock (12788)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5416	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 13,265 shares of Company stock on February 7, 2012 at prices ranging from $99.22 to $99.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2012 at each separate price.

F3: Represents volume-weighted average price of sales of 3,735 shares of Company stock on February 7, 2012 at prices ranging from $100.00 to $100.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2012 at each separate price.

F4: Represents volume-weighted average price of sales of 500 shares of Company stock on February 7, 2012 at prices ranging from $101.33 to $101.41. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2012 at each separate price.

F5: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F6: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.